The Rise Of Personalized Medicine Is Fueling The Growth Of The Market Due To Its Role In Enhancing Treatment Precision And Targeted Therapy Effectiveness: Transformative Forces Shaping the Molecular Targeted Therapy Market Landscape in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Molecular Targeted Therapy Industry Market Size Be by 2025?
In recent times, the market for molecular targeted therapy has experienced remarkable growth. Projected to increase from $65.78 billion in 2024 to $71.64 billion in 2025, it boasts a compound annual growth rate (CAGR) of 8.9%. The exceptional growth over the established period can be traced back to several factors including the increased occurrence of chronic diseases, surging demand for tailored medicinal approach, expanded use of biomarkers in drug creation, growing acceptance of monoclonal antibodies, and an uptick in the sanctioning of oncology treatment methods.

What's the Long-Term Growth Forecast for the Molecular Targeted Therapy Market Size Through 2029?
Expectations are high for robust expansion in the molecular targeted therapy market size in the coming years. It is projected to increase to $99.4 billion in 2029, with a compound annual growth rate (CAGR) of 8.5%. The surge during the predicted period can be ascribed to rising investments in cancer research, mounting demand for targeted immunotherapies, broadening clinical trial activities in precision medicine, an escalated use of companion diagnostics, and improving healthcare availability in developing economies. Key trends during the projection period encompass advancements in genomics technology, breakthroughs in drug delivery systems, augmented investment in research and development, progress in molecular diagnostics, and the embrace of AI technology for therapy exploration.

View the full report here:
https://www.thebusinessresearchcompany.com/report/molecular-targeted-therapy-global-market-report

What Are the Key Growth Drivers Fueling the Molecular Targeted Therapy Market Expansion?
The advancement of personalized medicine is predicted to spur the development of the molecular targeted therapy market. Personalized medicine takes into account an individual's genetic makeup, lifestyle, and environment to tailor prevention and treatment methods. This healthcare practice is booming due to the greater availability of genetic data, which allows for treatments to be customized to each person's genome, leading to improved effectiveness and reduced side effects. Personalized medicine enhances molecular targeted therapy by examining a patient's tumor for distinct genetic alterations or markers, facilitating the choice of therapies that directly address these irregularities. This method increases the accuracy of treatment and minimizes damage to healthy tissues. For example, the Personalized Medicine Coalition, a health care organization based in the U.S., reported in February 2024, that the FDA had given approval to 16 new personalized treatments for patients with rare diseases in 2023, a significant jump from the six approved in 2022. Therefore, the advancement of personalized medicine is fuelling the expansion of the molecular targeted therapy market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24609&type=smp

What Are the Key Trends Driving Molecular Targeted Therapy Market Growth?
Prominent businesses in the molecular targeted therapy sector are concentrating on the evolution of superior products like small molecule inhibitors, with objectives to enhance patient results in numerous cancers and chronic illnesses. These are tiny compounds capable of effortlessly infiltrating cells and impeding certain proteins triggering diseases. For example, in January 2025, US pharma company Amgen Inc. launched Lumakras (sotorasib) combined with Vectibix (panitumumab), which received authorization from the FDA, a US governance entity. It has been tailored for adult individuals suffering from KRAS G12C-mutated metastatic colorectal cancer who have previously undergone fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, as verified by an FDA-aproved examination. This endorsement relies on the Phase 3 CodeBreaK 300 investigation which revealed the combination significantly increased progression-free survival compared to the examined standard treatment, establishing it as the inaugural targeted therapy demonstrating such advantage in this chemotherapy-resistant patient group.

How Is the Molecular Targeted Therapy Market Segmented?
The molecular targeted therapy market covered in this report is segmented -

1) By Therapy Type: Monoclonal Antibodies, Small Molecule Inhibitors, Gene Therapy, Cell Therapy
2) By Mode Of Administration: Oral, Injectable, Topical, Intravenous
3) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Other Applications
4) By End-User: Hospitals, Clinics, Research Laboratories, Diagnostic Centers

Subsegments:
1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies
2) By Small Molecule Inhibitors: Tyrosine Kinase Inhibitors (TKIs), Proteasome Inhibitors, Poly Adenosine Diphosphate (ADP) Ribose Polymerase (PARP) Inhibitors, Mechanistic Target Of Rapamycin (mTOR) Inhibitors
3) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing
4) By Cell Therapy: Chimeric Antigen Receptor T-Cell Therapy, T-Cell Receptor (TCR) Therapy, Tumor-Infiltrating Lymphocytes (TILs) Therapy, Dendritic Cell Therapy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24609&type=smp

Which Companies Are Leading the Charge in Molecular Targeted Therapy Market Innovation?
Major companies operating in the molecular targeted therapy market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Amgen Inc., Regeneron Pharmaceuticals, Vertex Pharmaceuticals Incorporated, Novartis AG, Incyte Corporation, Exelixis Inc., IDEAYA Biosciences Inc., Prelude Therapeutics Incorporated, Gamida Cell Ltd., Adaptimmune Therapeutics plc, Engine Biosciences Pte. Ltd., Krystal Biotech Inc., Sotio Biotech a.s., Cybrexa Therapeutics Inc.

Which Regions Are Leading the Global Molecular Targeted Therapy Market in Revenue?
North America was the largest region in the molecular targeted therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molecular targeted therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report to*day:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24609

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.